Phenoxymethylpenicillin EQL is a prescription antibiotic used to treat common bacterial infections such as ear infections and Lyme disease in children and adults.

Phenoxymethylpenicillin EQL contains phenoxymethylpenicillin, a substance which has been registered as granules for oral solution/suspension in Sweden since 1978 under the trademark Kåvepenin^®. The market for phenoxmethylpenicillin granules for oral solution/suspension is estimated to approx. SEK 20 million in total annual sales in Sweden and Denmark.

The product is expected to be launched during EQL Pharma’s third financial quarter, 2021/22.

For further information, please contact:
Christer Fåhraeus
CEO, EQL Pharma AB (publ)

Phone: +46 (0) 705 – 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com

EQL Pharma AB (publ) in short
EQL Pharma AB specializes in developing and selling generics, i.e. medicines that are medically equivalent to originator medicines. The company currently has 18 niche generics (i.e. generics with little or no competition apart from the originator drug) approved in the Nordic markets. In addition to these, there exist a significant pipeline of additional niche generics for launch in 2020 and beyond. The business is currently entirely focused on prescription drugs. EQL Pharma AB conducts its operations in Lund, employs 9 people and is listed on the Spotlight Stock Market. EQL Pharma AB conducts extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU, India and China, among others.